These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
428 related articles for article (PubMed ID: 33078604)
21. Risk factors for COVID-19 mortality: The effect of convalescent plasma administration. Salazar MR; González SE; Regairaz L; Ferrando NS; González Martínez VV; Carrera Ramos PM; Muñoz L; Pesci SA; Vidal JM; Kreplak N; Estenssoro E PLoS One; 2021; 16(4):e0250386. PubMed ID: 33914780 [TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of convalescent plasma therapy in severe COVID-19 patients with acute respiratory distress syndrome. Allahyari A; Seddigh-Shamsi M; Mahmoudi M; Amel Jamehdar S; Amini M; Mozdourian M; Javidarabshahi Z; Eslami Hasan Abadi S; Amini S; Sedaghat A; Emadzadeh M; Moeini Nodeh M; Rahimi H; Bari A; Mozaheb Z; Kamandi M; Ataei Azimi S; Abrishami M; Akbarian A; Ataei P; Allahyari N; Hasanzadeh S; Saeedian N Int Immunopharmacol; 2021 Apr; 93():107239. PubMed ID: 33582019 [TBL] [Abstract][Full Text] [Related]
23. Adjunctive treatment with high-titre convalescent plasma in severely and critically ill COVID-19 patients - a safe but futile intervention. A comparative cohort study. Hoepler WP; Weidner L; Traugott MT; Neuhold S; Meyer EL; Zoufaly A; Seitz T; Kitzberger R; Baumgartner S; Pawelka E; Karolyi M; Grieb A; Hind J; Laferl H; Friese E; Wenisch C; Aberle SW; Aberle JH; Weseslindtner L; Jungbauer C Infect Dis (Lond); 2021 Nov; 53(11):820-829. PubMed ID: 34128763 [TBL] [Abstract][Full Text] [Related]
24. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. Joyner MJ; Carter RE; Senefeld JW; Klassen SA; Mills JR; Johnson PW; Theel ES; Wiggins CC; Bruno KA; Klompas AM; Lesser ER; Kunze KL; Sexton MA; Diaz Soto JC; Baker SE; Shepherd JRA; van Helmond N; Verdun NC; Marks P; van Buskirk CM; Winters JL; Stubbs JR; Rea RF; Hodge DO; Herasevich V; Whelan ER; Clayburn AJ; Larson KF; Ripoll JG; Andersen KJ; Buras MR; Vogt MNP; Dennis JJ; Regimbal RJ; Bauer PR; Blair JE; Paneth NS; Fairweather D; Wright RS; Casadevall A N Engl J Med; 2021 Mar; 384(11):1015-1027. PubMed ID: 33523609 [TBL] [Abstract][Full Text] [Related]
25. Convalescent plasma therapy in patients with COVID-19. Altuntas F; Ata N; Yigenoglu TN; Bascı S; Dal MS; Korkmaz S; Namdaroglu S; Basturk A; Hacıbekiroglu T; Dogu MH; Berber İ; Dal K; Kınık K; Haznedaroglu İ; Yılmaz FM; Kılıç İ; Demircioğlu S; Yosunkaya A; Erkurt MA; Turgut B; Caglayan M; Celik O Transfus Apher Sci; 2021 Feb; 60(1):102955. PubMed ID: 33011076 [TBL] [Abstract][Full Text] [Related]
26. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. RECOVERY Collaborative Group Lancet; 2021 May; 397(10289):2049-2059. PubMed ID: 34000257 [TBL] [Abstract][Full Text] [Related]
27. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
28. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial. Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924 [TBL] [Abstract][Full Text] [Related]
29. No SARS-CoV-2 RNA detected in the convalescent plasma of COVID-19 patients with different disease severity. Nomoto H; Kutsuna S; Okuma K; Kuramitsu M; Tezuka K; Ikebe E; Saito S; Kinoshita N; Terada M; Endo M; Suzuki T; Miyazato Y; Nakamoto T; Inada M; Hamaguchi I; Ohmagari N J Infect Chemother; 2021 Apr; 27(4):653-655. PubMed ID: 33487533 [TBL] [Abstract][Full Text] [Related]
30. Convalescent plasma - Is it useful for treating SARS Co-V2 infection? Ranganathan S; Iyer RN Indian J Med Microbiol; 2020; 38(3 & 4):252-260. PubMed ID: 33154232 [TBL] [Abstract][Full Text] [Related]
31. Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomes. Mendoza RP; Fyke W; Daniel D; Gabutan E; Das B; Bajaj H; Easy M; Vasileva A; Colbourn R; Alawad M; Dehghani A; Lin B; Emechebe D; Patel P; Jabbar A; Nikolov DB; Giovaniello D; Kang S; Tatem L; Bromberg K; Augenbraun M; Premsrirut P; Libien J; Norin AJ Hum Immunol; 2021 Apr; 82(4):255-263. PubMed ID: 33640208 [TBL] [Abstract][Full Text] [Related]
32. Hyperimmune plasma in three immuno-deficient patients affected by non-severe, prolonged COVID-19: a single-center experience. Cusi MG; Conticini E; Gandolfo C; Anichini G; Savellini GG; Valente S; Franchi F; Scolletta S; Percivalle E; Frediani B BMC Infect Dis; 2021 Jul; 21(1):630. PubMed ID: 34210259 [TBL] [Abstract][Full Text] [Related]